The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
The new project further expands the partner's long-term collaboration on new technologies for R&D
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
The cash consideration for the above acquisition will be Euro 26 million.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Subscribe To Our Newsletter & Stay Updated
